These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 14971813)

  • 21. Candida albicans is an immunogen for anti-Saccharomyces cerevisiae antibody markers of Crohn's disease.
    Standaert-Vitse A; Jouault T; Vandewalle P; Mille C; Seddik M; Sendid B; Mallet JM; Colombel JF; Poulain D
    Gastroenterology; 2006 May; 130(6):1764-75. PubMed ID: 16697740
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Novel anti-glycan antibodies related to inflammatory bowel disease diagnosis and phenotype.
    Seow CH; Stempak JM; Xu W; Lan H; Griffiths AM; Greenberg GR; Steinhart AH; Dotan N; Silverberg MS
    Am J Gastroenterol; 2009 Jun; 104(6):1426-34. PubMed ID: 19491856
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anti-neutrophil cytoplasmic antibodies in inflammatory bowel disease: do they recognize different subsets of a heterogeneous disease?
    Castellino F; Rosina F; Bansi DS; Bauducci M; Touscoz GA; Giorda L; Borghesio E; Bessone MP; Astegiano M; Musso A
    Eur J Gastroenterol Hepatol; 1995 Sep; 7(9):859-64. PubMed ID: 8574718
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mutations in CARD15 and smoking confer susceptibility to Crohn's disease in the Danish population.
    Ernst A; Jacobsen B; Østergaard M; Okkels H; Andersen V; Dagiliene E; Pedersen IS; Thorsgaard N; Drewes AM; Krarup HB
    Scand J Gastroenterol; 2007 Dec; 42(12):1445-51. PubMed ID: 17852840
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association of NOD2/CARD15 mutations on Crohn's disease phenotype in an Italian population.
    Bianchi V; Maconi G; Ardizzone S; Colombo E; Ferrara E; Russo A; Tenchini ML; Porro GB
    Eur J Gastroenterol Hepatol; 2007 Mar; 19(3):217-23. PubMed ID: 17301648
    [TBL] [Abstract][Full Text] [Related]  

  • 26. TNFalpha genotype influences development of IgA-ASCA antibodies in Crohn's disease patients with CARD15 wild type.
    Castro-Santos P; Mozo L; Gutiérrez C; Suárez A
    Clin Immunol; 2006 Dec; 121(3):305-13. PubMed ID: 16952484
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Diagnostic role of anti-Saccharomyces cerevisiae mannan antibodies combined with antineutrophil cytoplasmic antibodies in patients with inflammatory bowel disease.
    Kim BG; Kim YS; Kim JS; Jung HC; Song IS
    Dis Colon Rectum; 2002 Aug; 45(8):1062-9. PubMed ID: 12195191
    [TBL] [Abstract][Full Text] [Related]  

  • 28. pANCA and ASCA in the diagnosis of different subtypes of inflammatory bowel disease.
    Mokrowiecka A; Gasiorowska A; Malecka-Panas E
    Hepatogastroenterology; 2007; 54(77):1443-8. PubMed ID: 17708273
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Low Mannan-binding lectin serum levels are associated with complicated Crohn's disease and reactivity to oligomannan (ASCA).
    Schoepfer AM; Flogerzi B; Seibold-Schmid B; Schaffer T; Kun JF; Pittet V; Mueller S; Seibold F
    Am J Gastroenterol; 2009 Oct; 104(10):2508-16. PubMed ID: 19532127
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prevalence and significance of perinuclear anti-neutrophil antibodies (pANCA) in Romanian patients with Crohn's disease and ulcerative colitis.
    Preda CM; Vermeire S; Rutgeerts P; Joosens S; Diculescu M; Marica C; Ciocarlan M; Mirea V; Oproiu A
    Rom J Gastroenterol; 2005 Dec; 14(4):357-60. PubMed ID: 16400351
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Utility of serological markers in predicting the early occurrence of complications and surgery in pediatric Crohn's disease patients.
    Amre DK; Lu SE; Costea F; Seidman EG
    Am J Gastroenterol; 2006 Mar; 101(3):645-52. PubMed ID: 16464223
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combined type-1 plasminogen activator inhibitor and NOD2/CARD15 genotyping predicts complicated Crohn's disease behaviour.
    Alvarez-Lobos M; Arostegui JI; Sans M; Tassies D; Piu J; Reverter JC; Pique JM; Yagüe J; Panés J
    Aliment Pharmacol Ther; 2007 Feb; 25(4):429-40. PubMed ID: 17269998
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anti-neutrophil cytoplasmic antibodies in Brazilian patients with inflammatory bowel disease.
    Cabral VL; Miszputen SJ; Catapani WR
    Hepatogastroenterology; 2003; 50(50):412-5. PubMed ID: 12749235
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diagnostic precision of anti-Saccharomyces cerevisiae antibodies and perinuclear antineutrophil cytoplasmic antibodies in inflammatory bowel disease.
    Reese GE; Constantinides VA; Simillis C; Darzi AW; Orchard TR; Fazio VW; Tekkis PP
    Am J Gastroenterol; 2006 Oct; 101(10):2410-22. PubMed ID: 16952282
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serologic markers in inflammatory bowel disease: state of the art.
    Sandborn WJ
    Rev Gastroenterol Disord; 2004; 4(4):167-74. PubMed ID: 15580151
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anti-Saccharomyces cerevisiae mannan antibodies in familial Crohn's disease.
    Sendid B; Quinton JF; Charrier G; Goulet O; Cortot A; Grandbastien B; Poulain D; Colombel JF
    Am J Gastroenterol; 1998 Aug; 93(8):1306-10. PubMed ID: 9707056
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Interaction between seroreactivity to microbial antigens and genetics in Crohn's disease: is there a role for defensins?
    Lakatos PL; Altorjay I; Mándi Y; Lakatos L; Tumpek J; Kovacs A; Molnar T; Tulassay Z; Miheller P; Palatka K; Szamosi T; Fischer S; Papp J; ; Papp M
    Tissue Antigens; 2008 Jun; 71(6):552-9. PubMed ID: 18397186
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gene polymorphisms and serological markers of patients with active Crohn's disease in a clinical trial of antisense to ICAM-1.
    Yacyshyn BR; Schievella A; Sewell KL; Tami JA
    Clin Exp Immunol; 2005 Jul; 141(1):141-7. PubMed ID: 15958080
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Variants of CARD15 are associated with an aggressive clinical course of Crohn's disease--an IG-IBD study.
    Annese V; Lombardi G; Perri F; D'Incà R; Ardizzone S; Riegler G; Giaccari S; Vecchi M; Castiglione F; Gionchetti P; Cocchiara E; Vigneri S; Latiano A; Palmieri O; Andriulli A
    Am J Gastroenterol; 2005 Jan; 100(1):84-92. PubMed ID: 15654786
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Serological markers for prediction of response to anti-tumor necrosis factor treatment in Crohn's disease.
    Esters N; Vermeire S; Joossens S; Noman M; Louis E; Belaiche J; De Vos M; Van Gossum A; Pescatore P; Fiasse R; Pelckmans P; Reynaert H; Poulain D; Bossuyt X; Rutgeerts P;
    Am J Gastroenterol; 2002 Jun; 97(6):1458-62. PubMed ID: 12094865
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.